Daily Medication Pearl: Harvoni (Ledipasvir and Sofosbuvir)

Harvoni is a fixed-dose combination indicated for the treatment of chronic hepatitis C virus in adults and pediatric patients 3 years of age and older.

Medication Pearl of the Day:Harvoni (Ledipasvir and Sofosbuvir)

Indication: Harvoni is a fixed-dose combination of ledipasvir and sofosbuvir, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older.

Insight:

  • Dosing: Recommended dosage in adults 1 tablet (90 mg of ledipasvir and 400 mg of sofosbuvir) taken orally once daily with or without food.
  • Dosage form: Tablets 90 mg of ledipasvir and 400 mg of sofosbuvir; 45 mg of ledipasvir and 200 mg of sofosbuvir.
  • Adverse events (AEs): The most common AEs (incidence greater than or equal to 10%, all grades) observed from treatment with Harvoni were fatigue, headache, and asthenia.
  • Mechanism of action: Harvoni is a fixed-dose combination of an HCV NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor.
  • Manufacturer: Gilead

Sources: